Millennium Management LLC Purchases 516,094 Shares of Waters Corporation $WAT

Posted by Stanley Muller on Jun 18th, 2026

Millennium Management LLC lifted its position in Waters Corporation (NYSE:WAT – Free Report) by 2,281.7% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 538,713 shares of the medical instruments supplier’s stock after acquiring an additional 516,094 shares during the period. Millennium Management LLC’s holdings in Waters were worth $204,619,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. SG Americas Securities LLC grew its stake in shares of Waters by 543.8% in the fourth quarter. SG Americas Securities LLC now owns 37,244 shares of the medical instruments supplier’s stock valued at $14,146,000 after buying an additional 31,459 shares in the last quarter. Mackenzie Financial Corp grew its stake in shares of Waters by 12.2% in the third quarter. Mackenzie Financial Corp now owns 231,852 shares of the medical instruments supplier’s stock valued at $69,512,000 after buying an additional 25,182 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Waters by 3.3% in the third quarter. Vanguard Group Inc. now owns 7,656,891 shares of the medical instruments supplier’s stock valued at $2,295,612,000 after buying an additional 246,128 shares in the last quarter. Alberta Investment Management Corp bought a new position in shares of Waters in the third quarter valued at $4,677,000. Finally, Banque Cantonale Vaudoise grew its stake in shares of Waters by 329.0% in the fourth quarter. Banque Cantonale Vaudoise now owns 4,294 shares of the medical instruments supplier’s stock valued at $1,631,000 after buying an additional 3,293 shares in the last quarter. 94.01% of the stock is owned by institutional investors.

Waters Price Performance

NYSE:WAT opened at $357.02 on Thursday. Waters Corporation has a one year low of $275.05 and a one year high of $414.15. The company has a market cap of $35.06 billion, a P/E ratio of 45.36, a P/E/G ratio of 2.18 and a beta of 1.21. The firm’s fifty day moving average price is $340.94 and its two-hundred day moving average price is $348.84. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.79 and a quick ratio of 1.13.

Waters (NYSE:WAT – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $2.70 EPS for the quarter, beating the consensus estimate of $2.31 by $0.39. Waters had a net margin of 11.91% and a return on equity of 15.60%. The firm had revenue of $1.27 billion for the quarter, compared to the consensus estimate of $1.20 billion. During the same period in the previous year, the company earned $2.25 earnings per share. The company’s quarterly revenue was up 91.4% on a year-over-year basis. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. Equities analysts expect that Waters Corporation will post 14.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. TD Cowen raised their target price on shares of Waters from $345.00 to $385.00 and gave the company a “hold” rating in a research note on Wednesday, May 6th. Robert W. Baird set a $387.00 target price on shares of Waters in a research note on Wednesday, May 6th. Morgan Stanley reduced their price objective on shares of Waters from $423.00 to $350.00 and set an “equal weight” rating for the company in a research report on Sunday, February 22nd. Barclays upped their price objective on shares of Waters from $400.00 to $425.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Finally, Wolfe Research assumed coverage on shares of Waters in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $425.00 price objective on the stock. Three analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $394.56.

Check Out Our Latest Report on WAT

Waters Company Profile

(Free Report)

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.